Cargando…
Nanotechnology-based targeted drug delivery systems for lung cancer /
Nanotechnology-based Targeted Drug Delivery Systems for Lung Cancer is an indispensable resource that will help pharmaceutical scientists and clinical researchers design and develop novel drug delivery systems and devices for the treatment of lung cancer. As recent breakthroughs in nanomedicine are...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
London :
Academic Press,
2019.
|
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Front Cover; NANOTECHNOLOGY-BASED TARGETED DRUG DELIVERY SYSTEMS FOR LUNG CANCER; NANOTECHNOLOGY-BASED TARGETED DRUG DELIVERY SYSTEMS FOR LUNG CANCER; Copyright; Dedication; Contents; Contributors; Biography; Preface; 1
- An Overview of the Anatomy and Physiology of the Lung; 1. INTRODUCTION; 2. OVERVIEW OF THE ANATOMY OF LUNGS; 2.1 Gross Anatomy; 2.2 Tracheobronchial Tree; 2.3 Microscopic Structure of Trachea; 2.4 Microscopic Anatomy of the Lung; 2.5 Intrapulmonary Bronchus; 2.6 Bronchioles; 2.7 Alveolar Duct; 3. BLOOD SUPPLY OF THE LUNGS; 3.1 Pulmonary Arteries; 3.2 Pulmonary Veins
- 3.3 Bronchial Arteries3.4 Bronchial Veins; 3.5 Lymphatic Drainage of the Lungs; 3.6 Nerve Supply of the Lungs; 4. OVERVIEW OF THE PHYSIOLOGY OF THE LUNGS; 4.1 Mechanism of Breathing; 4.2 Inspiration; 4.3 Boyle's Law; 4.4 Physical Properties of the Lungs; 4.5 Compliance; 4.6 Elasticity; 4.7 Surface Tension; 5. EXPIRATION; 6. PULMONARY VENTILATION; 6.1 Lung Volumes and Capacities; 6.2 Dead Space; 7. GAS EXCHANGE; 7.1 Oxygen Transport in the Blood; 7.2 Factors That Affect Oxygen Carriage in Blood; 7.3 Transport of Carbon Dioxide in the Blood; 8. CONTROL OF RESPIRATION; 8.1 Chemoreceptors
- 9. CONCLUSIONAcknowledgments; References; 2
- An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer; 1. INTRODUCTION; 2. MOLECULAR ALTERATIONS IN LUNG CANCER: OPPORTUNITIES FOR THERAPY; 2.1 KRAS; 2.2 Epidermal Growth Factor Receptor (EGFR); 2.3 Anaplastic Lymphoma Kinase (ALK); 2.4 Vascular Endothelial Growth Factor Receptor (VEGFR); 2.5 BRAF; 3. CURRENT LUNG CANCER THERAPIES: FUTURE OF CANCER MEDICINE; 3.1 Surgery; 3.2 Radiation Therapy; 3.3 Chemotherapy; 3.4 Targeted Therapy/Personalized Medicine; 3.5 Targeting EGFR; 3.6 Targeting ALK
- 3.7 Antibodies3.8 Targeting Epigenetic Players; 3.9 Immunotherapy; 4. ROAD BLOCKS TO NSCLC THERAPIES: DRUG RESISTANCE AND METASTASIS; 4.1 Modified Membrane Transport; 4.2 Increased/Activated DNA Repair Pathway; 4.3 Faulty Apoptotic Pathways; 4.4 Alteration of Targets and Drug Metabolism; 4.5 Drug Resistance to Targeted Therapeutics; 5. CONCLUSION; References; 3
- Overexpressed Receptors and Proteins in Lung Cancer; 1. INTRODUCTION; 2. OVEREXPRESSED RECEPTORS/PROTEINS ON LUNG CANCER CELL SURFACES; 2.1 CXCL12/CXCR4; 2.2 Cluster of Differentiation 24; 2.3 Vasopressin and Oxytocin
- 2.4 Bombesin Receptors2.5 Fibroblast Growth Factor Receptors; 2.6 PETA-3/CD151; 2.7 NCAM/CD56; 2.8 Insulin-Like Growth Factor-1R; 2.9 Activated Leucocyte Adhesion Molecule/Cluster of Differentiation 166; 2.10 Bradykinin Receptor; 2.11 Epidermal Growth Factor Receptor; 2.12 Mer or Axl as Receptor Tyrosine Kinase; 2.13 Transcription Factors; 2.14 Interleukin-22 Receptor; 3. OVEREXPRESSED RECEPTORS/PROTEINS AFFECTING METABOLISM ON LUNG CANCER CELLS; 3.1 Stemlike Characteristics; 3.2 B-Cell-Lymphoma-2 (Bcl-2); 3.3 Expression of Cytochrome P4501B1; 4. CONCLUSION; Acknowledgments; References
- 4
- Polymeric Nanoparticle-Based Drug/Gene Delivery for Lung Cancer